McHugh, Domhnall
Sun, Bin http://orcid.org/0000-0002-8963-4100
Gutierrez-Muñoz, Carmen
Hernández-González, Fernanda
Mellone, Massimiliano
Guiho, Romain
Duran, Imanol
Pombo, Joaquim
Pietrocola, Federico
Birch, Jodie
Kallemeijn, Wouter W.
Khadayate, Sanjay
Dharmalingam, Gopuraja
Vernia, Santiago http://orcid.org/0000-0001-6728-5555
Tate, Edward W. http://orcid.org/0000-0003-2213-5814
Martínez-Barbera, Juan Pedro http://orcid.org/0000-0002-5292-7276
Withers, Dominic J. http://orcid.org/0000-0002-8009-7521
Thomas, Gareth J. http://orcid.org/0000-0003-3832-7335
Serrano, Manuel http://orcid.org/0000-0001-7177-9312
Gil, Jesús http://orcid.org/0000-0002-4303-6260
Article History
Received: 20 January 2021
Accepted: 12 October 2023
First Online: 27 November 2023
Competing interests
: J.G. has acted as a consultant for Unity Biotechnology, Geras Bio, Myricx Pharma Ltd and Merck KGaA, owns equity in Geras Bio and share options in Myricx Pharma Ltd, and is a named inventor in an MRC patent related to senolytic therapies (unrelated to the work described here). J.G. receives current funding from Pfizer (unrelated to this research). Unity Biotechnology funded research on senolytics in J.G.’s laboratory. E.W.T. is a founding director and shareholder of Myricx Pharma Ltd and a named inventor on patents covering NMT inhibitors (WO2017001812A1, PCT/GB2019/053613), is an advisor of and holds share options in Sasmara Therapeutics and receives current or recent funding from Myricx Pharma Ltd, Pfizer Ltd, Kura Oncology, AstraZeneca, Merck & Co. and GSK. D.M., E.W.T., W.W.K. and J.G. are named inventors on an Imperial College patent related to this work (WO 2022/090746A1). M.S. is a shareholder of Senolytic Therapeutics Inc., Life Biosciences Inc., Rejuveron Senescence Therapeutics AG and Altos Labs Inc., and was an advisor of Rejuveron Senescence Therapeutics AG and Altos Labs Inc. F.P. has acted as a consultant for Ono Pharma UK Ltd. The remaining authors declare no competing interests.